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Background: Positron emission tomography (PET) with [2-18 F]-2-fluoro-2-deoxy-D-glucose ([18 F]FDG-PET) was
acquired at multiple time-points a) to monitor the early response to RO5126766 (CH5126766) in xenograft models
b) to evaluate non-invasive small animal [18 F]FDG-PET imaging as a biomarker for MEK inhibitors for translation into
dose-finding studies in cancer patients and c) to explore the underlying mechanism related to FDG uptake in
tumors treated with RO5126766.
Methods: [18 F]FDG uptake was studied in HCT116 (K-ras), COLO205 (B-raf) mutants and COLO320DM (wild type)
xenografts from day 0 to 3 of RO5126766 treatment using a microPET Focus 120 and complemented with in vitro
incubations, ex-vivo phosphor imaging and immunohistochemical (IHC) analyses.
Results: In the HCT116 (K-ras) and COLO205 (B-raf) mutant xenografts, significant decreases in [18 F]FDG uptake were
detected in vivo on day 1 with 0.3 mg/kg and ex vivo on day 3 with 0.1 mg/kg RO5126766. [18 F]FDG changes correlated
with decreases in tumor cells proliferation (Ki-67) and with changes in expression levels of GLUT1. No effects were
observed in drug resistant COLO320DM cells. The cellular fractionation and Western blotting analyses suggested that the
change of [18 F]FDG uptake associated with RO5126766 is due to translocation of GLUT1 from membrane to cytosol,
similar to the results reported in the literature with EGFR tyrosine kinase inhibitors, which also target the MAPK pathway.
Conclusions: RO5126766 inhibition resulted in a rapid time - and dose - dependent decline in [18 F]FDG uptake in both
mutant xenografts. These results strongly resemble the clinical observations obtained with MEK/Raf inhibitors support
the use of preclinical [18 F]FDG-PET as a translational tool for decision support in preclinical and early clinical
development of MEK inhibitors.
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The Ras/Raf/mitogen-activated protein kinase kinase
(MEK)/extracellular signal-regulated (ERK) cascade trans-
mits signals from the cell surface receptors to the
nucleus and regulates cell cycle progression, cell prolif-
eration, survival, differentiation and transformation. The
genetic mutations in many of the components in this* Correspondence: tetyana.tegnebratt@ki.se
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The Ras/Raf/MEK/ERK pathway has a well-defined role in
cancer biology and has become an important target in the
development of cancer therapeutics [1-3]. Many drugs
targeting the ligand-activated receptor tyrosine kinases
and their downstream effectors such as Ras, Raf and MEK
are currently being tested in clinical trials [4-7].
A major drawback in the clinical testing of the new
drugs is the lack of pharmacodynamic biomarkers at
early stage clinical trials. Non-invasive imaging tech-
niques have demonstrated a potential for acceleratings is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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response and early identification of responders [8-10].
Positron emission tomography (PET) imaging with the
fluorine-18 labeled glucose analog 2-fluoro-2-deoxy-D-
glucose ([18 F]FDG-PET) is increasingly being included
as a new functional endpoint in phase I to III clinical
trials in oncology, in addition to conventional endpoints
such as toxicity and decreases in tumor size. Many of
these clinical studies have reported that [18 F]FDG-PET
imaging can be successfully used for monitoring the
efficacy of a range of targeted therapies [11-13].
MEK has a critical position in the Ras/Raf/MEK/ERK
pathway with few direct upstream activators (e.g. Raf )
and few downstream targets (e.g., ERK). The successful
development of MEK inhibitors and their evaluations in
various clinical trials is well summarized in recent re-
views [14,15]. [18 F]FDG-PET imaging has been included
as a therapeutic read-out in several of these studies
[16-18]. PET/CT imaging was also used as a primary
therapeutic endpoint for sorafenib, inhibitor of Raf
kinase activity [19].
Despite these applications of [18 F]FDG-PET as an effi-
cacy biomarker for MEK inhibitors in humans, very few
preclinical studies have been reported. Early studies
demonstrated instead the utility of the thymidine analog
3’-deoxy-3’-18 F-fluorothymidine (FLT) for therapeutic
monitoring of the MEK inhibitor PD0325901 in a
V600EB-raf mutant SK-MEL-28 melanoma model [8,20].
[18 F]FDG-PET was used to evaluate inhibitors of PI3K/
AKT/mTOR and epidermal growth factor receptor
(EGFR) pathways either alone or in combination with a
MEK inhibitor. For instance, PET/CT together with
magnetic resonance imaging demonstrated the synergis-
tic effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor,
and ARRY-142886 (AZD6244/selumetinib), an allosteric
MEK inhibitor, on K-ras mutated tumor in a genetically
engineered mouse model of lung adenocarcinoma [21].
The value of using [18 F]FDG-PET as an early surro-
gate marker has been demonstrated in several preclinical
models. Studies in xenografts sensitive to gefitinib, an
EGFR tyrosine kinase inhibitor (EGFR-TKI), revealed up
to a 55% decrease in [18 F]FDG uptake within 48 hours
after start of treatment [9]. [18 F]FDG-PET could also be
a surrogate marker for the efficacy of erlotinib, another
EGFR-TKI, in preclinical human head and neck carcin-
oma models [22] and of the c-KIT inhibitor, imatinib, in
models with activating c-KIT mutations in gastrointes-
tinal stromal tumors (GISTs). Preclinical PET imaging
revealed that [18 F]FDG uptake in tumors sensitive to
the drug was significantly reduced as early as 4 hours
after imatinib treatment while no response was observed
in resistant tumors [23].
The main goal of our study was to explore whether
the effects of MEK/Raf inhibitors in humans revealedwith [18 F]FDG-PET could be replicated in animals and
whether [18 F]FDG-PET can therefore be used in preclin-
ical models as an endpoint for early detection of thera-
peutic activity and dose-finding studies for this class of
inhibitors. For this purpose, we have used RO5126766,
a first-in-class orally active and highly selective dual
protein kinase inhibitor, specific for Raf and MEK.
RO5126766 is a novel chemical class allosteric inhibitor
of MEK activity and prevents MEK from phosphoryl-
ation by Raf through stable Raf-MEK complex forma-
tion. RO5126766 inhibits ERK signalling more effectively
that a standard MEK inhibitors. It suggests a new thera-
peutic approach for ras tumors by blocking feedback ac-
tivation of ERK signalling [24]. RO5126766 has shown
potent in vivo anti-tumor efficacy in diverse human
tumor xenografts models and has recently been evalu-
ated in a phase I dose-escalation study in humans in
which [18 F]FDG-PET was included as one of the bio-
marker assessments [18,25]. Our results show that
in vivo [18 F]FDG-PET imaging of preclinical tumor
models can be used to successfully monitor therapeutic
response to MEK inhibition.
Methods
Cell culture and reagents
The human colon cancer cell lines HCT116, COLO205
and COLO320DM were purchased from the American
Type Culture Collection (ATCC). All cells were
maintained in the designated media and indicated con-
centrations of heat-inactivated fetal bovine serum
(Gibco) and L-glutamine (Sigma) according to the ATCC
recommendations. Cells were grown at 37°C in an
atmosphere of 5% CO2. RO5126766 (CH5126766) was
synthesized in Chugai Pharmaceuticals Co., Ltd. For
in vitro and in vivo studies, the drug was dissolved in
DMSO (Wako Chemicals GmbH) to yield a 2.5 mg/mL
stock solution concentration and stored at -20°C. The
solutions of RO5126766 used for in vitro and in vivo
experiments were freshly prepared on each experimental
day. The vehicle and RO5126766 stock solutions were
diluted 1:20 with the diluent (10.5% aqueous solution
of 2-hydroxypropyl-β-cyclodextrin (Celdex HP- β-CD,
HPCD, Sigma)) on each dosing day.
[18 F]FDG uptake in vitro
[18 F]FDG uptake was determined in untreated HCT116,
COLO205 and COLO320DM cells as well as treated
with vehicle only as a control or RO5126766 at indicated
concentrations. 1×105 cells/well were seeded in 6-well
plates (Costar®) together with appropriate doses of
RO5126766 for indicated times. Cell culture medium
was changed to glucose-free and 0.37 MBq of [18 F]FDG
was added to each well and incubated for 1 hour in 5%
CO2 atmosphere at 37°C. The cells were washed three
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using a 1480 Automatic gamma counter Wizard3
(Perkin Elmer). [18 F]FDG incorporation was determined
and expressed relative to total protein concentration.
Protein content was determined using the Thermo
Scientific Pierce BCA Protein Assay Kit (Waltham, USA).
Cellular fractionation and Western blotting
Plasma membrane fractionation was performed using
a membrane protein extraction kit from BioVision.
According to the manufacturer's recommendations,
5×108 HCT116 cells were used for protein extraction.
The purity of the plasma membrane protein fraction was
assessed by Western blot analysis of the plasma mem-
brane marker (mouse monoclonal antibodies to Na+,
K+-ATPase from Abcam). For Western blot analysis,
15 μg of plasma membrane-associated or of the cytosol
proteins were separated on 4-12% poly-acrylamide gels
(Invitrogen) and Western blotting was performed. The
rabbit polyclonal antibodies to glucose transporters
GLUT1 and GLUT3 were from Abram (Cambridge,
UK). (Secondary HRP-linked anti-mouse and anti-rabbit
IgG were from Cell Signaling (In Vitro Sweden AB,
Stockholm, Sweden). Bands were visualized with Western
blotting Luminol Reagent (Santa Cruz). The images were
captured using a LAS-1000 from Fujifilm or exposed to
X-ray film (Fujifilm, Tokyo).
Xenograft tumor models
Female athymic nude (nu/nu) mice, age 5–6 weeks (18-22 g)
were purchased from Scanbur AB (Sollentuna, Sweden).
Animal care, handling and health monitoring were carried
out in accordance with the Guidelines for Accommodation
and Care of Laboratory Animals. All animal experiments
were performed in accordance with protocols approved by
the Institutional Animal Care committee.
For the tumor xenografts, 5×106/mouse human cancer
colon carcinoma cells were inoculated subcutaneously in
the right flank of Balb-nu/nu mice. Once tumors were
established (150–200 mm3), mice were randomized into
groups with similar mean tumor volumes at the start of
the study. Tumor volume and body weight were measured
two times per week. Tumor volumes were determined with
digital caliper using the formula (tumor length × width2)/2.
Tumor growth inhibition (TGI) was calculated using the
following formula: TGI = [1− (T −T0)/(C −C0)] × 100,
where T and T0 are the mean tumor volumes on a specific
experimental day and on the first day of treatment, respect-
ively, for the experimental groups and likewise, where C
and C0 are the mean tumor volumes for the control group.
The daily administration of RO5126766 was performed
orally at doses 0.1, 0.3 and 1.0 mg/kg. The doses were
selected based on the results of preliminary studies. The
maximal tolerated dose (MTD) was defined as themaximum dose associated with <20% weight loss and no
toxic deaths. The MTD in the three xenograft models was
1.5 mg/kg for RO5126766.
MicroPET imaging
MicroPET imaging was performed by standard protocols
as described previously [26]. Mice were fasted for 6–8
hours prior to start of imaging session [27]. [18 F]FDG
(obtained as an aliquot from daily clinical productions at
Karolinska University Hospital, 7–8 MBq per mouse, max-
imum volume of 200 μl) was administered to awake,
warmed (37°C) mice by a bolus injection via the tail vein.
Forty to sixty minutes after the tracer injection, the mice
were anaesthetized with isoflurane, controlled by an E-Z
anaesthesia vaporizer (5% initially and then 1.5% to main-
tain anaesthesia, blended with 7:3 air/O2 and delivered
through a Microflex non-rebreather mask from Euthanex
Corporation, Palmer, PA). The mice were placed on a
heating pad (37°C) on the camera bed, with most of the
body in the field-of-view (7.68 cm). Emission data were
collected for 20 minutes in list mode with MicroPET Focus
120 scanner (CTI Concorde Microsystems). Data were
processed using MicroPET Manager (CTI Concorde
Microsystems). PET data were acquired in fully three-
dimensional (3-D) mode and images were reconstructed by
standard 2-D filtered back projection using a ramp filter.
The matrix size of the reconstructed images was 128 ×
128 × 95 with a spatial resolution of 1.3 mm. Data were
corrected for randoms, dead time and decay. Standard
Uptake Values (SUV) were calculated for 3D regions of
interest (ROI), using Inveon Research Workplace software
(Siemens Medical Solutions). Tumor ROIs drawn on the
images employed a 75% threshold of the maximum inten-
sity voxel. The ROI counts were normalized to the injected
dose and body weight and converted to SUV. The drug
effect on tumor metabolism was estimated as%SUVmax
change day 1, 2, or 3 compared to day 0 (baseline).
Ex-vivo phosphor imaging
Immediately after the last MicroPET scan, the animals
were sacrificed and their tumors were rapidly frozen.
Tumor slices (20 μm thickness) were obtained using a
cryomicrotome (CM 3050S, Leica Microsystems, Wetzlar,
Germany) and were placed on Superfrost Plus microscope
slides (Menzel-Glaser, Germany). The sections were
placed in a BAS exposure cassette with a 2325 imaging
plate (Fujifilm Corporation, Japan) and exposed for at least
1 hour. The quantitative autoradiography data (photo-
stimulated luminescence, PSL, unit/mm2) were normal-
ized to the injected dose and body weight.
Immunohistochemistry
Tumor slices were obtained as described above. Frozen
tumor slices sections were kept at −80°C until needed.
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fixed for 10 minutes with ice-cold acetone. The slides
were incubated in 2.5% normal horse blocking serum in
PBS before primary antibodies, rabbit polyclonal to
Ki-67 (Abcam), were added followed by incubation for
1 hour. As the secondary antibody, ImmPRESS™ reagent,
anti-rabbit Ig, peroxidase (Vector) was used. The
staining’s were visualized by using an ImmPact™ DAB
substrate kit (Vector). The counter stain was performed
in methyl green for 2 minutes at room temperature. The
images were analyzed with an Olympus UC30 digital
color camera (Olympus Color Management Technology)
and Cell Imaging software for Life Sciences microscopy.
Statistical analysis
Statistical significance was examined by Student t test.
P-values less than 0.05 were considered a statistically
significant difference.
Results
Effects of RO5126766 on cellular determinants of the
uptake and retention of [18 F]FDG
We first investigated in vitro the feasibility of using two
RO5126766 sensitive cell lines, HCT116 (G13DK-ras) and
COLO205 (V600EB-raf ), and one resistant cell line
COLO320DM (no K-ras and B-raf mutation) for [18 F]
FDG-PET imaging. The study revealed variations in glu-
cose utilization between the three cell lines. The highest
cellular glucose uptake was observed in COLO320DM
cells and lowest in COLO205 (Additional file 1: figure
S1). The RO5126766 at the concentration of 0.3 μM was
a minimal dose demonstrated reduction of ERK/MEK
phosphorylation to undetectable levels in HCT116
(K-ras) cells after 2 hours of the treatment start [24].
Variations in [18 F]FDG uptake in tumor cells exposed to
RO5126766 were subsequently examined with 0, 0.3 or
1.3 μM of RO5126766 up to 48 hours. There was no
significant change in the cellular accumulation of [18 F]
FDG in the drug-resistant COLO320DM during treat-
ment (Figure 1a). In HCT116 cells, a significant reduc-
tion in [18 F]FDG uptake was observed after 24 h of
treatment (67.1%, p < 0.05, Figure 1b) and not at earlier
time points. In contrast, in drug-sensitive COLO205
cells, a dose-dependent decrease in [18 F]FDG uptake
was observed as early as after 2 hours of treatment
compared to control (54.8%, p < 0.01, Figure 1c).
In order to identify the cellular components determin-
ing the uptake and retention of [18 F]FDG in these cell
lines, the expression levels of glucose transporters
(GLUTs) and hexokinases were analyzed by Western
blotting. GLUT1 was detected in all cell lines. GLUT3
was expressed in COLO320DM and HCT116 but not in
COLO205 cells. Hexokinase II was expressed in all
cell lines (Figure 1d). To further examine possiblemechanisms behind the RO5126766-induced changes in
[18 F]FDG uptake, we used the HCT116 cell line because
of its higher basal glucose utilization. We detected sig-
nificant decreases in the expression of the cellular trans-
membrane protein GLUT1 in the plasma membrane
fraction after 24 hours of treatment with 1.3 μM of
RO5126766, compared to the vehicle treated cells. In
parallel, an increase of GLUT1 in the cytosol fraction
was observed during treatment (Figure 1e). We did not
detect significant changes in hexokinase II activity
during the treatment of HCT116 cells with 1.3 μM of
RO5126766 for 24 hours (Figure 1f ).
Anti-tumor activities of RO5126766 and FDG-PET imaging
results in human colon carcinoma xenografts in balb
nu/nu mice
In vitro experiments demonstrated that RO5126766
treatment resulted in dose-dependent decreases in [18 F]
FDG uptake for both K-ras and B-raf mutants, but not for
COLO320DM, the resistant cell line. Furthermore, PET
imaging of antitumor activities of RO5126766 and quanti-
fication of early response in the three colorectal cancer
xenograft models were evaluated on days 0 and 3 of the
treatment. Once the tumors were established (approxi-
mately 0.2 cm3) and mice were divided into treatment
groups (n = 10/group) and treatment was initiated with
vehicle and RO5126766 at 0.1, 0.3 or 1.0 mg/kg daily oral
gavage for 9 days. RO5126766 treatment (1.0 mg/kg) did
not inhibit growth of the COLO320DM tumors (Figure 2a)
and these mice were therefore sacrificed after 6 days of
treatment when the tumors had reached the size limits
allowed by research ethics. In contrast, RO5126766 treat-
ment showed dose-dependent tumor growth inhibition
(TGI) in the mice with xenografts of both the mutant
models. In HCT116 (K-ras) tumor xenografts the treat-
ment resulted in 80% TGI (0.1 mg/kg), 119% TGI
(0.3 mg/kg, p < 0.01) and 157% TGI (1.0 mg/kg, p < 0.01)
(Figure 2b). In the COLO205 (B-raf) mutant tumor xeno-
grafts TGI’s of 120% (0.3 mg/kg, p < 0.01) and 190%
(1.0 mg/kg, p < 0.01) (Figure 2c) were achieved.
[18 F]FDG uptake was measured in tumors of mice
treated with RO5126766 at 0.1, 0.3 or 1.0 mg/kg versus
vehicle from day 0 (baseline) to day 3. PET imaging
revealed no significant effect on [18 F]FDG uptake in
COLO320DM tumors during the treatment (Figure 2d).
In contrast, RO5126766 treatment HCT116 (K-ras)
tumors demonstrated significant decrease in metabolic
activity on day 3, compared to day 0 (p < 0.05 at 0.3- and
1.0 mg/kg doses and vehicle (p < 0.01). No significant
effect was observed in the 0.1 mg/kg dosing group
(Figure 2e). Despite the low basal [18 F]FDG-uptake in
COLO205 tumor xenografts, we could detect inhibition
by RO5126766 at both 0.3 mg/kg (p < 0.05) and 1.0 mg/
kg (p < 0.05) doses. Representative coronal PET images
Figure 1 Effects of RO5126766 on cellular determinants of the uptake and retention of [18 F]FDG: (a) COLO320DM (wild type);
(b) HCT116 (K-ras mutant) (c) COLO205 (B-raf) mutant) cells were treated with RO5126766 for the indicated time- and dosage range
and FDG uptake was assessed *p<0.05; **p<0.01; (d) Western blotting analysis of the GLUTs and hexokinase II levels in three cell
lines, actin is a loading control; (e) GLUT1 expression in plasma-membrane and cytosol fractions of HCT116 (K-ras) cells, treated with
RO5126766 (1.3 μM). Na+, K+-ATPase and actin protein levels in the cell membrane and cytosolic fractions (respectively) served as the
fractions purity and loading controls; (f) Western blotting analysis of the hexokinase II activity in three cell lines, treated for 24 hours
with RO5126766, 1.3 μM. Actin is a loading control.
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in COLO320DM (wt) tumors, HCT116 (K-ras) and
COLO205 (B-raf), respectively, at days 0 and 3 of treat-
ment with vehicle versus RO5126766 (only 1.0 mg/kg
dose shown).
The HCT116 tumors demonstrated higher basal [18 F]
FDG-uptake and were usually more readily distinguished
from background tissues than COLO205 tumors. There-
fore, additional PET scans and ex-vivo phosphor imaging
for earlier time points than day 3 and one lower dose were
performed using HCT116 xenografts. Serial microPET im-
aging revealed significant decreases in tumor [18 F]FDG
uptake as early as on day 1 after administration of 0.3 mg/
kg RO5126766 (Figure 3a, representative coronal images).
Maximum reductions of [18 F]FDG-uptake tumors treated
with RO5126766, 0.3 mg/kg on day1, day2 and day3 were
17% (p < 0.01), 19% (p = 0.15) and 35% (p < 0.05) compared
with baselines values, respectively (Figure 3b).
Phosphor imaging of [18 F]FDG uptake and
immunohistochemistry in excised tissue sections
In the mice bearing HCT116 xenografts that received
the lowest dose RO5126766 (0.1 mg/kg), statisticallysignificant changes in [18 F]FDG uptake could not be
detected by PET on day 3 (Figure 2e). As a complement
to PET, ex-vivo phosphor imaging at higher resolution
and sensitivity was also performed (Figure 4a,b, repre-
sentative images). Tumors were sectioned after PET im-
aging and exposed to phosphor imaging plates together
with a blood sample from the same mouse. We observed
higher radioactivity concentrations ([18 F]FDG uptake)
in tumors on day 0 compared to day 3 of treatment
(Figure 4a). Hematoxylin & eosin examination revealed no
difference in examined tumors morphology (Figure 4b).
The result was confirmed by statistical analysis of the [18 F]
FDG uptake in a larger population of mice (n = 6, p < 0.01)
(Figure 4c). However, the ex vivo technique of course only
gave one time point per animal and could not be used for
monitoring individual responses over time.
Histopathology in RO5126766 treated mice
The tumors that were subjected to ex-vivo phosphor im-
aging and excised from mice treated with 0.1 mg/kg
RO5126766 on day 3 were also analyzed histologically
(hematoxylin & eosin, H&E) and immunohistochemically
(Ki-67) (Figure 5a, b). The difference in [18 F]FDG uptake
Figure 2 Anti-tumor activities of RO5126766 and FDG-PET imaging results in human colon carcinoma xenografts in Balb nu/nu mice.
Mice bearing (a) COLO320DM (wt) (b) HCT116 (K-ras) and (c) COLO205 (B-raf) mutant tumor xenografts were orally administered once daily for
9 days with vehicle, 0.1, 0.3 or 1.0 mg/kg of RO5126766. The tumor sizes are mean ± SD (n = 10). Error bars = standard error, **p < 0.01. FDG-PET
imaging was performed at baseline (day 0) and day 3 after the treatment with RO5126766 in (d) COLO320DM (wt) (only high dose) (e) HCT116
(K-ras) and (f) COLO205 (B-raf). The SUVmax values are mean ± SE (n = 6). *p < 0.05, **p < 0.01. Representative PET images (coronal sections) of
(g) COLO320DM (wt) (h) HCT116 (K-ras) and (i) COLO205 (B-raf) tumors on days 0 (baseline) and 3 of the treatment with RO5126766, 1 mg/kg.
Tumors are shown in the boxed areas, twofold magnifications. All images scaled to the same color scale.
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detected with Ki-67 antigen. Figure 5c shows the number
of proliferating cells on day 0 (baseline) and day 3 after
therapy.
Discussion
In this study we have demonstrated the feasibility of
using [18 F]FDG-PET imaging as an early surrogate end-
point for monitoring biological and anti-tumor activity
of MEK/Raf inhibitors given for the treatment of human
cancers. We first used in vitro experiments to investigate
whether RO5126766 effects on sensitive tumor cells
would be accompanied by changes in the uptake of
labeled glucose. We found that [18 F]FDG uptake wasreduced in a dose (0.3-1.3 μM) - and time (0-48 h) -
dependent manner in HCT116 and COLO205 tumor cells
carrying K-ras and B-raf mutations, respectively, whereas
RO5126766 did not affect [18 F]FDG uptake in
COLO320DM cells, which has no mutation in these two
genes and no apparent levels of phospho-MEK and
phospho-ERK in the cells. Both mutant tumor cell lines
demonstrated metabolic sensitivity to the drug, confirming
their feasibility for [18 F]FDG-PET imaging of RO5126766
efficacy. However, in vitro results showed variations in
basal [18 F]FDG-uptake among three cell lines, with the
lowest levels observed in COLO205.
The transport of glucose through the cell membrane
via glucose transporter proteins and its subsequent
Figure 3 Serial FDG-PET imaging results in HCT116 (K-ras) tumors at early times after treatment with RO5126766, 0.3 mg/kg.
(a) Coronal PET images from one mouse presenting vehicle - (upper panel) and RO5126766 treated group on days 1, 2 and 3 of treatment.
Tumors are shown in the boxed area, twofold magnification. (b) Comparison of changes in [18 F]FDG uptake from baseline to day 1, day 2 and
day 3 of treatment, presented as% change SUVmax value to baseline (*p < 0.05; **p < 0.01). The SUVmax values are mean + SE (n = 5).
Figure 4 Ex-vivo phosphor imaging and quantitative autoradiography data. Ex-vivo phosphor imaging of radioactivity distribution (a) on day 0
and day 3 of the treatment HCT116 (K-ras) tumor-bearing mice with RO5126766, 0.1 mg/kg. The small image in the right corner is the radioactivity in a
blood sample (20 μL) from each individual mouse used as a reference to normalize the tumor radioactivity uptake. In box: vital tumor area with highest
radioactivity uptake and (b) corresponding H&E staining. (c) Quantitative autoradiography data presented as ratio of photo-stimulated luminescence, PSL,
unit/mm2 to radioactivity uptake in the blood sample and normalized to the injected dose and body weight (**p< 0.01, n = 6).
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Figure 5 Representative immunohistochemical images of Ki-67 positive cells in HCT116 (K-ras) xenografts in mice treated with a
lowest dose RO5126766 (0.1 mg/kg). (a) tumor morphology, visualized with H&E staining (left image) and corresponding Ki-67 positive
staining (brown cells, right image) before the treatment start (baseline) and (b) after 3 days of treatment with RO5126766 (0.1 mg/kg).
(c) Quantitative assessment of proliferating index of tumor cells in relation to RO5126766 treatment based on IHC staining of Ki-67 antigen of
excised, acetone fixed frozen tumor tissue (*p < 0.05, n = 3).
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steps required for its cellular accumulation [28]. The ex-
pression levels of glucose transporters and hexokinases
are changed in many cancers [29,30]. Chung et al. [31]
suggested that increased numbers of glucose trans-
porters at the plasma membrane of cancer cells may be
a cause of increased [18 F]FDG uptake, at least in colon
cancers. Yun et al. [32] reported that GLUT1 expression
levels were consistently upregulated and that glucose
uptake was enhanced in K-ras and B-raf mutated cells
compared to wild type cells. Drug-induced changes in
[18 F]FDG uptake together with the expression levels of
GLUTs and hexokinases in tumor cells may therefore
serve as good predictors for how well [18 F]FDG-PET
can be used for monitoring response in vivo in xeno-
grafts from a particular cell line. We observed that
GLUT1 expression levels decreased in the plasma mem-
brane and increased in the cytosol fractions of HCT116
cells treated with RO5126766. These results are indicative
of a RO5126766-induced translocation of GLUT1 from the
plasma membrane to the cytosol, which could be a possible
mechanism behind the observed reductions in [18 F]FDG
uptake in the drug-treated cells. Similar translocation
effects on glucose transporters have been reported for the
EGFR inhibitors, gefitinib [9] and erlotinib [22].
This study shows that in RO5126766-sensitive cells
MEK and Raf inhibition results in a rapid decrease in
[18 F]FDG uptake. In contrast, in COLO320DM resistant
cells (no detectable pMEK and pERK levels, suggesting
no activation of RAF and MEK), RO5126766 did not
affect the glucose uptake. These results support theapplicability of FDG-PET as a pharmacodynamic bio-
marker for MEK/Raf inhibitors.
In vivo imaging revealed significant reductions in [18 F]
FDG uptake as early as after 1 day of treatment with
0.3 mg/kg of RO5126766 in both HCT116 and
COLO205 xenografts (37% and 43% , respectively). The
FDG change paralleled but preceded the drug-induced
reductions in xenograft sizes. In HCT116 tumors the
[18 F]FDG uptake was increasingly reduced over time (for
example, at the dose of 0.3 mg/kg, for 17% at day 1, 19%
at day 2 and 35% on day 3) and exposure-dependent,
showing a decrease from baseline on day 3 (range from
97 to 52% at the doses range 0.1-1.0 mg/kg) compared
to an increase in vehicle treated group (126%). These
observations are consistent with reports elsewhere of
early decreases in [18 F]FDG uptake for mTOR inhibition
in experimental lymphoma model [33], and for combined
PI3K/mTOR (PF-04691502) and MEK (PD-0325901)
inhibitors in a K-ras G12D; Pten mutated mouse model of
ovarian cancer [34].
Partial volume effects associated with imaging tissues
close in size to the 1–2 mm resolutions of small animal
PET and the heterogeneous nature of tumors including
varying amounts of necrosis and non-tumor tissue can
affect in vivo quantifications [35]. In order to account
for these limitations and further validate the results
obtained, we used PET imaging combined with ex vivo
phosphor imaging to evaluate minimal effective doses
and times for RO5126766 efficacy in the tumor xeno-
grafts. With an order of magnitude higher resolution,
ex vivo phosphor imaging can serve as a useful single
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mation obtained from small animal PET imaging [36].
Using ex vivo phosphor imaging, reductions in [18 F]
FDG uptake could also be detected even for the lowest
administered dose (0.1 mg/kg) on day 3 of treatment in
HCT116 tumors. We also observed high [18 F]FDG up-
take in necrotic-free tumor fractions of vehicle treated
mice, compared to low uptake in tumors of the drug
treated animals. Thus ex vivo tissue sampling was help-
ful in defining the dose- and time- dependency while
using microPET to examine MEK inhibition at selected
doses over time.
[18 F]FDG uptake reductions in drug-treated tumors
correlated with decreased number of proliferating cells
in RO5126766 treated tumors measured with Ki67. This
is in agreement with recently published studies sugges-
ting that cellular proliferation and metabolism are tightly
linked processes that share common regulatory pathways
in tumour cells [37]. It has been shown [38,39] that
some oncoproteins (such as Ras, c-Myc, Akt) participate
in the control of cancer cell metabolism. Therefore, in
addition to the metabolic studies with [18 F]FDG, we also
investigated the proliferation status of the tumor cell
lines during treatment with RO5126766. In this study,
we observed significant decreases in the number of pro-
liferating cells in HCT116 tumors upon exposure to the
drug, which supports also the use of proliferation PET
tracers such as [18 F]FLT [40] for evaluating the anti-
proliferative activity of RO5126766.
Both EGFR-TKIs, for which [18 F]FDG-PET as already
demonstrated utility in monitoring efficacy [8], and
MEK/Raf inhibitors are targeting the MAPK pathway.
EGFR inhibitors block the initiation of the pathway at
the upstream receptor site while MEK/Raf inhibitors
block pathway signaling at one of the effector sites
downstream from the receptor. In our study, we ob-
served similarities between the effect obtained with the
MEK/Raf inhibitor and the one reported in the literature
with EGFR inhibitor. In both cases drug treatment was
associated with a reduction of FDG-PET uptake and in
both cases this was accompanied by a translocation of
GLUT1 from the plasma membrane to the cytosol. The
similarity observed between MEK/Raf and EGFR inhibi-
tors provides further evidence that cellular glycolytic
metabolism as measured by the uptake and retention of
[18 F]FDG provides an effective downstream pharmaco-
dynamic read-out for therapeutic strategies targeting in-
hibition of signaling components of the MAPK pathway.
These preclinical studies were performed in parallel
with phase 1 dose escalation clinical studies of the dual
inhibitor, RO5126766, in patients with locally advanced
and/or metastatic solid tumors without specific geno-
type. The reduction in FDG uptake observed in the
current pre-clinical study mimics the results observedclinically. In both studies, the decrease in FDG uptake
was dose dependent with similar overall reduction in
FDG uptake (approximately 35% on day 3 in drug-sensitive
xenograft models (HCT116, COLO205) compared to 28%
on day 15 in patients with melanoma [18]).Conclusions
Our preclinical PET imaging studies support the use of
[18 F]FDG-PET imaging as an early pharmacodynamic
biomarker in preclinical studies of MEK and Raf inhibi-
tors, with strong decreases in SUVmax observed as early as
24 hours post treatment. The decrease in [18 F]FDG up-
take was dose-dependent and increased with treatment
exposure, therefore strongly paralleling and supporting
the observations obtained with this class of compounds in
patients [18,25]. The effect in [18 F]FDG uptake in vitro
was more rapid in B-raf mutant cell line COLO205,
reflecting the increased sensitivity of B-raf mutated tu-
mors to MEK inhibition. Data obtained by cellular frac-
tionation and Western blotting suggest that the change of
[18 F]FDG uptake associated with MEK inhibition might
be due to translocation of GLUT1 from membrane to
cytosol. A future study, using preclinical dynamic [18 F]
FDG-PET imaging and kinetic parameters analysis in re-
sponse to RO5126766 treatment and its correlation with
our in vitro findings would be very interesting.Additional file
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